日気食会報，73（2），20225） Tahara M, Kiyota N, Nibu KI, et al：Real-world safety and effectiveness of nivolumab for recur-rent or metastatic head and neck cancer in Ja-pan：a post-marketing surveillance. Int J Clin On-col 26（9）：1619─1627, 2021.6） 内閣府：令和2年版高齢社会白書（全体版）令和元年度 高齢化の状況及び高齢社会対策の実施状況．2020.7） Extermann M, Aapro M, Bernabei R, et al：Use of comprehensive geriatric assessment in older cancer patients：recommendations from the task force on CGA of the International Society of Geri-atric Oncology（SIOG）．Crit Rev Oncol Hematol 55（3）：241─252, 2005.8） Mohile SG, Dale W, Somerfield MR, et al：Practi-cal assessment and management of vulnerabilities in older patients receiving chemotherapy：ASCO guideline for geriatric oncology. J Clin Oncol 36（22）：2326─2347, 2018.9） Presley CJ, Gomes F, Burd CE, et al：Immuno-therapy in older adults with cancer. J Clin Oncol 39（19）：2115─2127, 2021.10） Elias R, Giobbie-Hurder A, McCleary NJ, et al：Efficacy of PD-1 & PD-L1 inhibitors in older adults：a meta-analysis. J Immunother Cancer 6（1）：26, 2018.11） 山﨑知子：頭頸部がん薬物療法を行うものが知っておくべきステロイド投与時の注意点．頭頸部癌46（1）：26─30, 2020.12） Krishnan M, Teply BA, Yu F, et al：Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors. J Clin Oncol 38（15_sup-pl）：12028, 2020.13） Kanesvaran R, Cordoba R, Maggiore R：Immuno-therapy in older adults with advanced cancers：implications for clinical decision-making and fu-ture research. Am Soc Clin Oncol Educ Book, American Society of Clinical Oncology annual meeting, Vol.38, pp.400─414, 2018.14） Brahmer JR, Lacchetti C, Schneider BJ, et al：Management of immune-related adverse events in patients treated with immune checkpoint inhibi-tor therapy：American Society of Clinical Oncolo-gy Clinical Practice Guideline. J Clin Oncol 36（17）：1714─1768, 2018.15） Martins F, Sofiya L, Sykiotis GP, et al：Adverse effects of immune-checkpoint inhibitors：epidemi-ology, management and surveillance. Nature Re-views Clinical Oncology 16：563─580, 2019.82
元のページ ../index.html#46